Sanofi Invests $16.02 Million in Maplight Therapeutics, Inc. $MPLT

Sanofi acquired a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT) in the 4th quarter, Holdings Channel reports. The firm acquired 912,041 shares of the company’s stock, valued at approximately $16,020,000. Maplight Therapeutics comprises approximately 5.2% of Sanofi’s holdings, making the stock its 6th biggest holding.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Strs Ohio purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $53,000. TD Asset Management Inc purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $649,000. Seven Grand Managers LLC purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $1,756,000. Blue Owl Capital Holdings LP purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $5,745,000. Finally, Geode Capital Management LLC purchased a new position in shares of Maplight Therapeutics in the fourth quarter valued at $6,835,000.

Maplight Therapeutics Price Performance

NASDAQ MPLT opened at $28.01 on Friday. Maplight Therapeutics, Inc. has a 12 month low of $12.24 and a 12 month high of $33.28. The company has a market capitalization of $1.19 billion and a price-to-earnings ratio of -0.68. The company’s fifty day moving average price is $27.36 and its two-hundred day moving average price is $20.94.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). As a group, analysts anticipate that Maplight Therapeutics, Inc. will post -5.04 EPS for the current year.

Insider Activity

In other news, CEO Christopher A. Kroeger sold 118,235 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $27.19, for a total value of $3,214,809.65. Following the transaction, the chief executive officer directly owned 1,394,094 shares in the company, valued at approximately $37,905,415.86. This trade represents a 7.82% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James Woodruff Lillie sold 24,811 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $28.76, for a total transaction of $713,564.36. Following the completion of the transaction, the insider owned 243,450 shares in the company, valued at approximately $7,001,622. The trade was a 9.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 495,244 shares of company stock worth $14,079,461 over the last ninety days. Insiders own 3.80% of the company’s stock.

Wall Street Analyst Weigh In

MPLT has been the subject of several analyst reports. Stifel Nicolaus upped their target price on shares of Maplight Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday. HC Wainwright restated a “buy” rating and issued a $45.00 target price on shares of Maplight Therapeutics in a research note on Thursday, May 28th. Needham & Company LLC started coverage on shares of Maplight Therapeutics in a research note on Wednesday, April 8th. They issued a “buy” rating and a $37.00 target price for the company. Canaccord Genuity Group started coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They set a “buy” rating and a $35.00 price objective on the stock. Finally, Lifesci Capital upgraded shares of Maplight Therapeutics to a “strong-buy” rating in a research note on Thursday, May 14th. Three analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $37.78.

Maplight Therapeutics Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.